COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,398 Articles (22,816 medRxiv, 8,582 bioRxiv)

Most recent first Previous |  Page 1005: Articles 10041-10050  | Next

The value of vaccine booster doses to mitigate the global impact of the Omicron SARS-CoV-2 variant
Hogan, A. M., Wu, S. L., Doohan, P., Watson, O. J., Winskill, P., Charles, G., Barnsley, G., Riley, E. M., Khoury, D. S., Ferguson, N. M., Ghani, A.
10.1101/2022.01.17.22269222 — Posted: 2022-01-18
Estimation of the COVID-19 Average Incubation Time:Systematic Review, Meta-analysis and SensitivityAnalyses
Weng, Y., Yi, G. Y.
10.1101/2022.01.17.22269421 — Posted: 2022-01-18
Non-Communicable Diseases Risk Factors and the Risk of COVID-19 Infection among University Employees in Indonesia
Widyahening, I. S., Vidiawati, D., Pakasi, T. A., Soewondo, P., Ahsan, A.
10.1101/2022.01.17.22269249 — Posted: 2022-01-18
SARS-CoV-2 induces human endogenous retrovirus type W envelope protein expression in blood lymphocytes and in tissues of COVID-19 patients.
Charvet, B., Brunel, J., Pierquin, J., Iampietro, M., Decimo, D., Queruel, N., Lucas, A., del Mar Encabo-Berzosa, M., Arenaz, I., Perez Marmolejo, T., Valezka Bolanos Morales, F., Ivan Gonzalez Gonzalez, A., Castorena Maldonado, A., Luna Rivero, C., Mathieu, C., Kury, P., Flores-Rivera, J., Avila Rios, S., Salgado Montes de Oca, G., Schoorlemmer, J., Horvat, B., Perron, H. J.
10.1101/2022.01.18.21266111 — Posted: 2022-01-18 Discussion: Onsite
Booster vaccination to curtail COVID-19 resurgence - population-level implications of the Israeli campaign
Gavish, N., Yaari, R., Huppert, A., Katriel, G.
10.1101/2022.01.18.22269141 — Posted: 2022-01-18
Effectiveness of mRNA COVID-19 Vaccines against Omicron among Veterans
Young-Xu, Y.
10.1101/2022.01.15.22269360 — Posted: 2022-01-18
Selection analysis identifies unusual clustered mutational changes in Omicron lineage BA.1 that likely impact Spike function
Martin, D. P., Lytras, S., Lucaci, A. G., Maier, W., Gruning, B., Shank, S. D., Weaver, S., MacLean, O. S., Orton, R. J., Lemey, P., Boni, M. F., Tegally, H., Harkins, G. W., Scheepers, C., Bhiman, J. N., Everatt, J., Amoako, D. G., San, J. E., Giandhari, J., Sigal, A., NGS-SA, , Williamson, C., Hsiao, N.-y., von Gottberg, A., De Klerk, A., Shafer, R. W., Robertson, D. L., Wilkinson, R. J., Sewell, B. T., Lessells, R., Nekrutenko, A., Greaney, A. J., Starr, T. N., Bloom, J. D., Murrell, B., Wilkinson, E., Gupta, R. K., de Oliveira, T., Kosakovsky Pond, S. L.
10.1101/2022.01.14.476382 — Posted: 2022-01-18
Mucociliary Transport Deficiency and Disease Progression in Syrian Hamsters with SARS-CoV-2 Infection
Li, Q., Vijaykumar, K., Phillips, S., Hussain, S. S., Huynh, V. N., Fernandez-Petty, C. M., Peabody Lever, J. E., Foote, J. B., Ren, J., Campos-Gomez, J., Daya, F. A., Hubbs, N. W., Kim, H., Onuoha, E., Boitet, E. R., Fu, L., Leung, H. M., Yu, L., Detchemendy, T. W., Schaefers, L. T., Tipper, J. L., Edwards, L. J., Leal, S. M., Harrod, K. S., Tearney, G. J., Rowe, S. M.
10.1101/2022.01.16.476016 — Posted: 2022-01-18
Evidence of increased Cathepsin B/L and decreased TMPRSS2 usage for cell entry by the SARS-CoV-2 Omicron variant
Padmanabhan, P., Dixit, N. M.
10.1101/2022.01.13.476267 — Posted: 2022-01-18
ASGR1 is a candidate receptor for SARS-CoV-2 that promotes infection of liver cells
Yang, X., Zhu, Y., Zhao, X., Liu, J., Xun, J., Yuan, S., Chen, J., Pan, H., Yang, J., Wang, J., Liang, Z., Shen, X., Liang, Y., Lin, Q., Liang, H., Li, M., Lu, H., Zhu, H.
10.1101/2022.01.15.476426 — Posted: 2022-01-18

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).